Nanoscope Therapeutics announced its participation in the Association for Research in Vision and Ophthalmology (ARVO) 2026 annual meeting and Eyecelerator@ARVO 2026, taking place in Denver, Colorado.

The company will present new clinical and preclinical data supporting its multi-characteristic opsin (MCO) platform, including long-term results in patients with retinitis pigmentosa (RP).

“Sustained, multi-year vision improvement from a one-time treatment has the potential to be truly transformative for patients and further underscores the promise of MCO-010," said Dr. Samuel Barone, Chief Medical Officer of Nanoscope. "As we move closer to completing our BLA submission and preparing for commercialization, we believe Nanoscope’s momentum continues to build.”

Nanoscope’s leadership will contribute to discussions on the future of regenerative medicine during Eyecelerator@ARVO:

  • Panelist: Dr. Samarendra Mohanty, President and Chief Scientific Officer
  • Session Title: Is Vision Improvement on the Horizon for Regenerative Medicine?
  • Session: S5
  • Date & Time: Friday, May 1, 11:45 a.m. – 12:45 p.m. MDT
  • Location: Bluebird Ballroom, Colorado Convention Center

At the ARVO Annual Meeting, Nanoscope and collaborators will present multiple studies highlighting both viral and non-viral delivery approaches for its MCO therapies:

  • Dr. Saurav Mohanty will present preclinical findings on MCO-020, a non-viral therapy, focusing on biodistribution and retinal expression in primates using near-infrared laser-activated gold nanorods.
    • Session: AMD: New Drugs, Delivery Systems, and Mechanisms of Action I
    • Date & Time: Sunday, May 3, 8:00 – 9:45 a.m. MDT
  • Dr. Vinit Mahajan of Stanford University will present three-year data from the RESTORE Phase 2b/3 trial of MCO-010, demonstrating sustained vision improvement in RP patients.
    • Session: Inherited Retinal Disease
    • Date & Time: Tuesday, May 5, 8:30 – 8:45 a.m. MDT
  • Dr. Samarendra Mohanty will also present research on contralateral transfer and retinal transduction following unilateral delivery of MCO-010 using an AAV vector.
    • Session: Gene Therapies and Editing
    • Date & Time: Wednesday, May 6, 2:00 – 3:45 p.m. MDT

“Three-year findings from the RESTORE trial demonstrate that MCO-010 can provide durable functional benefit for patients with retinitis pigmentosa and further support the promise of optogenetic approaches to vision restoration,”  said Allen Ho, MD, Director of Retina Research at Wills Eye Hospital and Chief Medical Advisor for Nanoscope. "The additional data on MCO-010 (AAV) and MCO-020 (non-viral) platforms in non-human primates expand our understanding of delivery dynamics and support continued advancement of these programs.”

Nanoscope’s MCO platform is designed as a one-time, in-office intravitreal therapy that restores light sensitivity by targeting surviving bipolar cells in the retina. According to Nanoscope, unlike many gene therapies, the treatment does not require genetic testing, invasive surgery, or repeated dosing, making it broadly applicable to patients with various forms of photoreceptor degeneration, including retinitis pigmentosa, Stargardt disease, and geographic atrophy.

The company will also host attendees at Booth 6065 throughout the ARVO conference.